Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.025 2.17% 1.175 1,959,178 11:09:45
Bid Price Offer Price High Price Low Price Open Price
1.10 1.25 1.175 1.15 1.15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.45 -1.41 -0.22 13
Last Trade Time Trade Type Trade Size Trade Price Currency
15:46:52 O 397,492 1.25 GBX

Feedback (FDBK) Latest News

More Feedback News
Feedback Investors    Feedback Takeover Rumours

Feedback (FDBK) Discussions and Chat

Feedback Forums and Chat

Date Time Title Posts
25/1/202119:10FEEDBACK plc Medical Imaging Technology7,335
04/11/201907:39Feedback 35
01/11/201815:33****Feedback PLC****3,006
03/2/201011:50Feedback looks interesting - could easily be a ten bagger over next year396
03/9/200210:53ainsley long .........................quick shart it2

Add a New Thread

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-25 15:46:541.25397,4924,968.65O
2021-01-25 15:39:021.251742.17O
2021-01-25 15:16:101.2580210.00O
2021-01-25 15:00:341.2580210.00O
2021-01-25 13:20:121.1510,000115.00O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.15p.
Feedback Plc has a 4 week average price of 1.05p and a 12 week average price of 0.98p.
The 1 year high share price is 2.40p while the 1 year low share price is currently 0.35p.
There are currently 1,066,931,686 shares in issue and the average daily traded volume is 1,508,422 shares. The market capitalisation of Feedback Plc is £12,536,447.31.
lr2: You shouldn't be here if you expect Bleepa to only get a small fraction of the NHS communications market Yump. It would be seen as a failure for a product with two unique selling points. I'm assuming the company might get 15% of the possible NHS comms market in the next two years. 15% of £72 mil is £10.8 mil. That should be more than enough to value Feedback as a growth company and rate it as at least £100 mil mcap. £100 mil / 1,067,000 shares would be a share price of 0.937p. That will do for starters.
lr2: Congrats on the 20 bagger Brasso. Best I've managed was a 17 bagger. I think we can make double figures here Brasso. Check out the below info. Https:// NHS England workforce. Consultants - 49,585 Junior Doctors - 57,394 Other Doctors - 11,302 _____________________ Subtotal - 118,281 Nurses and Health Visitors - 298,071 Scientific, therapeutic and technical staff - 147,729 Midwifes - 22,141 Ambulance staff - 16,707 _____________________ Subtotal - 484,648 118,281 + 484,648 = 602,929 doctors, nurses etc in NHS England. Income per annum for Bleepa on 100% take up - 602,929 x £10 per month x 12 months = £72,351,480. No GP's, no dentists, no vets (oh yes) and no armed forces (again oh yes) included in figures. No medical staff for for Ireland, Wales & Scotland included in figures. No overseas sales (India & Arabia for instance) included in figures. Only CE certified product, only clinical quality imaging product. Two very strong USPs. In short not much opposition to Bleepa at this time. Expect sign ups to really take off in next financial year as hospitals have overspent in current financial year (bloody Covid). NHSx should provide some income over next few months I'd hope, though it must be a hard sell to get this into hospitals overwhelmed by Covid. Who has the time to integrate a new comms system in an active hospital environment during a pandemic? Bank a few million in revenue over next few months with more coming in from April onwards would be my hope. Never underestimate that hospitals will already have already signed up for comms packages whether it be pagers, Medic Bleep etc. These on-going agreements will need to end before taking on Bleepa but make no mistake the hospitals will have to do this if they want the security of a CE marked and clinical quality imaging product. These are Bleepa's unique selling points. No other UK, European, Asian company can match them. I might have seen one in the USA but not 100% certain about that yet - it's a private company and full info is very difficult to obtain. When Feedback bring in £10 million revenue a year wouldn't you expect a market capitalisation of something over £100 million? That will put the share price into low double figures and that is only the beginning of what can be achieved here.
lr2: Having a golden oldies morning and watching the share price rise. This one's from the first album I bought after returning to the UK from my stay in Iran. Https://
yump: As we are in lockdown, I've been given some DIY to do, so literally will be watching paint dry, rather than the FDBK share price. Just as well really.
yump: Bleepa was announced 27 July 2019. Its an app. There were no apps before. Its a new product. Most people are hopeful because of that, not FDBK's historic product range. FDBK are pinning their future on it. So its a startup in everything except the fact that FDBK have been going for years.
lr2: And here's the rest. The share price was up 15% as I speak on an jolly statement from the company’s big cheese. He claims that the company has had a ‘transformative year’ during which it developed its main product. This is known as ‘Bleepa’ which Feedback describes as ‘the revolutionary medical imaging communications app’. Bleepa allows doctors to view patients’ conditions in close up at high resolution from their phones or whatever other devices they choose. Feedback started the current year by raising just over £5 million which it needed to expand. And it’s likely to do that because Bleepa is the only such medical imaging system on the NHS’s computer network with a coveted CE marked as a ‘Class I medical device.’ I think that shows deep respect in the hospital world. Also, Feedback has entered a new partnership with an outfit called Axial3D, allowing medics to view and manipulate 3D pictures on their computers. There’s little doubt that more clinicians are becoming more reliant on the Feedback computer images as time goes on. To try to speed up the process, the firm has strengthened its marketing team. Its cash position is perky at £4.4 million, so that gives the share a measure of security. Meanwhile, demands on medical services continue to grow and Feedback offers a system that should make things a lot easier for those at the start-end. The company’s record of making money is poor, which has depressed the share price, but that might soon change. Unlike the Punter’s Return. Never miss a story.
lr2: Yes. Hello, Share Followers. A company for which I have high hopes still to be realised is Feedback plc (FDBK). On the face of it this AIM company which enables doctors and surgeons to see what’s going on in the human body should enjoy a buoyant share price. Yet it’s been disappointing for some time now. However, with much more focus on medical services these days, perhaps its time has come… Will need to register to see more.
lr2: Christmas shopping for the grandkids before lock down then Derby vs QPR (0-1) so a bit late replying to your IQAI post Duc. I see IQAI ended up 183% on an RNS that basically says IQAI have a non-exclusive agreement with the owners of the LSN software, AI metrics, to manufacture, market, and distribute the LSN software platform now the FDA have granted market clearance in the USA. Not sure how IQAI plan to benefit much from this. I don't believe they have any manufacturing presence in the USA, nor any marketing and distribution personnel there either. Could this latest RNS just be another of Trevor Brown's ways of pumping up the IQAI share price prior to another placing? Let's see what tomorrow brings price wise for IQAI? I wouldn't be surprised to see an almighty fall because I sure as hell can't see today's RNS adding much value to IQAI's bottom line unless I've totally missed something of value. Edit - a quick search of the Net tells me that LSN is going to be an independent plugin to OsiriX DICOM viewer that users will pay for independently of the monthly costs of the core OsiriX platform. There's even been a draft user manual available for the last 6 months. So the information about LSN has been out there for awhile. Https:// If this is worth a 183% rise in IQAI share price I will be amazed.
sonie01: They could get Edelman (worlds biggest PR company) as their PR representative but that is not going to help share price, we need contracts! There's nigh on a billion shares, more demand for shares could increase the price per share but as usual it'll sink again to 1p! The only way is contracts for this to get out of single digits into double digits. At 10p a share the company will be valued at £100m, so income would have to hit £5m with a P/E of 20
ducatiman: Robo, that is your decision. The Jury is still out on fdbk. They have been serial disappointers. If you believe the new team are astute businessmen and therefore they are hiring a number of new staff because they are going to need them, then, it would seem that the share price is currently cheap. If, however, you think they are hiring in the hope of new business and FDBK is being run by “spivs in white coats” trying to eek out a lifestyle through AIM, then run for the hills!
Feedback share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210126 03:50:34